Eliahu Heldman

USPTO Granted Patents = 11 (Patent Applications = 19)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 108(Granted Patents)

Company Filing History:

5 out of 344

Ben-gurion University of the Negev Research and Development Authority

State of Israel, Represented by Prime Minister's Office, Israel

patent

4. 1 out of 3

State of Israel, Represented by the Prime Minister's Office, Israel

Years Active: 1989-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11304964 - Bolaamphiphilic compounds, compositions and uses thereof (2022-04-19),

2. 10842747 - Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery (2020-11-24),

3. 9642803 - Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery (2017-05-09),

4. 8921356 - Compositions comprising nicotinic agonists and methods of using same (2014-12-30),

5. 8377469 - Nano- and mesosized particles comprising an inorganic core, process and applications thereof (2013-02-19),

6. 8273731 - Compositions comprising nicotinic agonists and methods of using same (2012-09-25),

7. 7939562 - Amphiphilic derivatives for the production of vesicles, micelles and complexants, and precursors thereof (2011-05-10),

8. 7887833 - Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting (2011-02-15),

9. 6746688 - Apparatus for the transdermal treatment of Parkinson's disease (2004-06-08),

10. 5106831 - Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine (1992-04-21),

11. 4855290 - Derivatives of quinuclidine (1989-08-08),

Title: Eliahu Heldman: Innovator in Pharmaceutical Compositions

Introduction

Eliahu Heldman, an accomplished inventor based in Rehovot, Israel, has made significant contributions to the field of pharmaceutical sciences. With a total of 11 patents to his name, he has focused on developing innovative compounds and delivery systems aimed at improving drug efficacy, particularly for critical applications such as HIV treatment.

Latest Patents

Among his latest patents, Eliahu Heldman introduced the concept of bolaamphiphilic compounds, described by the formula I: HG-L-HG. These compounds are specifically designed to facilitate the delivery of HIV active drugs into the brain, which is essential for treating central nervous system infections. Another notable patent involves the creation of nano-sized particles that include multi-headed amphiphiles. These particles are capable of selectively releasing biologically active agents, thus enhancing targeted drug delivery systems.

Career Highlights

Eliahu Heldman has collaborated with notable institutions, including the Ben-Gurion University of the Negev Research and Development Authority. His work there has laid the groundwork for significant advancements in the field. Additionally, he has been associated with Neuroderm Ltd., a company recognized for its innovative approaches to drug delivery.

Collaborations

Throughout his career, Eliahu has had the pleasure of working alongside esteemed colleagues such as Charles Linder and Sarina Grinberg. These collaborations have undoubtedly contributed to the depth and breadth of his research, fostering an environment of shared innovation and discovery.

Conclusion

Eliahu Heldman's contributions to pharmaceutical innovation showcase the importance of creativity and collaboration in addressing complex medical challenges. His pioneering work in bolaamphiphilic compounds and targeted drug delivery methods continues to pave the way for future advancements in treatment options.

This text is generated by artificial intelligence and may not be accurate.